Vertex: Planning Trial Supplies Using Tourtellotte Software – Bio-IT World.
Related articles
- A Non-Earnings Boost for Vertex (fool.com)
- Why You Should Be Bullish On Vertex Now (seekingalpha.com)
- Vertex surges as rival hep C contender plays catch-up in clinic (fiercebiotech.com)
- Bristol-Myers’ Hepatitis Stumble Boosts Gilead, Vertex (minyanville.com)
- Vertex Wins EU Approval for Cystic Fibrosis Drug (xconomy.com)
- Vertex Is Tomorrow’s Monster Stock (fool.com)
- Slice and Dice Data and Investors Will Slice You (fool.com)
- A Non-Earnings Boost for Vertex (dailyfinance.com)
- An Assault On Vertex, Enthusiasm Building Around Xoma (seekingalpha.com)
- After Big Oops, Vertex Plows Ahead With Cystic Fibrosis Drug Combo (xconomy.com)
You must be logged in to post a comment.